• Arizona Hemophilia Association to Host Zombie Walk 9 in Downtown Phoenix
  • Because Words Matter, Is It Disease or Disorder?
  • PRO Instruments Offer Reliable Data to Assess Hemophilia Patients, Study Shows
  • Certain B-Cells in Spleen Show Potential as Therapeutic Targets to Reduce FVIII Inhibitors in Hemophilia A, Study Shows
  • CSL Behring LEAD Grants Support Patient Advocacy Efforts by Local Bleeding Disorder Groups
  • Does it Feel Buzzy or Achy?
  • Catalyst’s Recombinant Factor IX Variant for Hemophilia B Wins FDA Orphan Drug Status
  • Catalyst Successfully Completes First Subcutaneous Factor IX Dosing Group in Hemophilia B Clinical Trial
  • Prophylaxis Improves Function, Quality of Life, and Pain Relief in Hemophilia A, Study Finds
  • Parental Dynamics: Holding It Together
  • ICER Draft Report on Emicizumab as Potential Hemophilia A Therapy Now Open to Public Review
  • Bioverativ, Bicycle Therapeutics to Jointly Develop New Therapies for Rare Blood Disorders